<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Autoantibodies against glial fibrillary acidic protein (GFAP) were investigated by ELISA test in sera of patients suffering from senile <z:hpo ids='HP_0000726'>dementias</z:hpo> and in healthy aging people </plain></SENT>
<SENT sid="1" pm="."><plain>One hundred eight subjects divided into control, vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VD), presenile <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD), and senile <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SDAT</z:e>) groups were included in the study </plain></SENT>
<SENT sid="2" pm="."><plain>VD patients showed the highest antibody titers when compared to controls, whereas AD had the lowest titers when compared to the other groups </plain></SENT>
<SENT sid="3" pm="."><plain>These results do not support the utility of anti-GFAP antibodies as useful markers of <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e>, suggesting that their presence is a secondary phenomenon to blood-brain barrier disruption </plain></SENT>
</text></document>